Triumeq：三合一抗艾药，效果和安全都经过严格测试

The effectiveness of triumeq has been demonstrated in multiple studies. A pivotal trial involving 833 previously untreated patients showed that 88% of those treated with triumeq had undetectable HIV levels after 48 weeks, compared to 81% of those treated with another triple-drug regimen (Atripla). These findings support the authorization of triumeq in the EU.

Common side effects associated with triumeq include insomnia, headaches, nausea, diarrhea, and fatigue. For a complete list of potential risks and adverse reactions, refer to the package leaflet.

Tridemq should not be used concurrently with certain medications, such as fingolimod (used for treating multiple sclerosis), as this can increase the drug's levels in the body and lead to severe side effects. Severe hypersensitivity reactions may also occur, particularly in individuals with the HLA-B*5701 genotype. After evaluating its efficacy and safety, the European Commission concluded that triumeq has been sufficiently proven effective for previously untreated patients and authorized its use in the EU. This authorization means triumeq can be prescribed to treat HIV/AIDS patients and help improve their quality of life.

• Vemlidy：新型抗病毒药，对付慢性乙肝的好选择  2024-09-13

• 阿曲普拉在欧盟获批用于抗HIV  2024-09-13

• Genvoya：对抗HIV-1的强力抗病毒药  2024-09-13

• 泰博司他韦：增强抗HIV效果的给力药物  2024-09-13

• 奥德赛：对抗HIV-1的抗病毒新药  2024-09-13

• Truvada： Effective HIV Treatment And Protection Against STDs  2024-09-13

• Rekambys，一种治疗HIV1感染的新药  2024-09-13

• Eviplera：新型药物高效治疗HIV-1感染  2024-09-13